In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grunenthal GmbH

www.grunenthal.com

Latest From Grunenthal GmbH

Merck Makes Its Debut In Pain With Pioneering New Analgesic Class

Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.

Innovation Deals

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

A Grunenthal First: Establishing A US Presence With A Tailored Marketing Strategy

Germany's pain-focused specialty pharmaceutical firm is adding America to its commercial reach, through acquiring New York's Averitas Pharma to jumpstart its push to commercialize products on its own account, via a niche approach.

 

Deals Rare Diseases

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register